Abstract
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by the degeneration of both upper and lower motor neurons in the brain and spinal cord. ALS is associated with protein misfolding and inclusion formation involving RNA-binding proteins, including TAR DNA-binding protein (TDP-43) and fused in sarcoma (FUS). The 125-kDa Matrin3 is a highly conserved nuclear DNA/RNA-binding protein that is implicated in many cellular processes, including binding and stabilizing mRNA, regulating mRNA nuclear export, modulating alternative splicing, and managing chromosomal distribution. Mutations in MATR3, the gene encoding Matrin3, have been identified as causal in familial ALS (fALS). Matrin3 lacks a prion-like domain that characterizes many other ALS-associated RNA-binding proteins, including TDP-43 and FUS, however, our bioinformatics analyses and preliminary studies document that Matrin3 contains long intrinsically disordered regions that may facilitate promiscuous interactions with many proteins and may contribute to its misfolding. In addition, these disordered regions in Matrin3 undergo numerous post-translational modifications, including phosphorylation, ubiquitination and acetylation that modulate the function and misfolding of the protein. Here we discuss the disordered nature of Matrin3 and review the factors that may promote its misfolding and aggregation, two elements that might explain its role in ALS pathogenesis.
Introduction
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease in the United States, belongs to a specific category of neurodegenerative diseases known as motor neuron diseases. These diseases are characterized by the degeneration of both the upper motor neurons (Betz cells) in the primary motor cortex, and the lower motor neurons in the anterior horn cells of the spinal cord (van Es et al., 2017; Masrori and Van Damme, 2020). The onset of ALS is age-dependent with the majority of patients diagnosed in the sixth decade of life. ALS affects approximately two in 100,000 individuals, with higher prominence in males than in females (Ingre et al., 2015), and an increased risk for military veterans (Kurtzke and Beebe, 1980; McKee and Robinson, 2014) and athletes (). Typically, ALS leads to death in 2–4 years after onset, killing an estimated 30,000 people worldwide each year (Petrov et al., 2017).
ALS presents clinically with progressive muscle weakness, paralysis, and respiratory failure, which is the major cause of death in patients. ALS can be classified based on its heritability; patients with sporadic ALS (sALS), have no family history of the disease, while patients with familial ALS (fALS) do; sALS accounts for approximately 90% of all cases (Zarei et al., 2015). There is no effective treatment for ALS, with the current standard of care focusing on a multidisciplinary approach to symptom management, employing respiratory and nutritional support, as well as pharamcological interventions (Mejzini et al., 2019). Unfortunatley, riluzole (Rilutek™) (; Lacomblez et al., 1996; ) and edaravone (Radicava™/Radicut) () are the only two FDA-approved medications for treating ALS, and studies show that they can only delay the onset of ventilator-dependence and extend the lifespan of a patient by two to 3 months (Kiernan et al., 2011). Given that oxidative stress (Li et al., 2013; Pollari et al., 2014) and glutamate excitotoxicity (Foran and Trotti, 2009) are two key elements in the biochemistry of ALS, much research has been directed in developing molecules that target these pathways (Petrov et al., 2017; Jaiswal, 2019). In fact, while exact mechanism remains unknown, riluzole and edaravone appear to target elements of glutamate release from motor neurons (; Jaiswal et al., 2006; Jaiswal, 2017), and ROS production and elimination (Yamamoto et al., 1996; Pérez-González and Galano, 2011), respectively. In any case, most of the attempts to produce novel molecules have been frustratingly unsuccessful (Petrov et al., 2017) and further research needs to identify effective therapeutic targets and strategies for the treatment of ALS, including targeting protein misfolding (Nevone et al., 2020).
ALS and other neurodegenerative disorders, such as Alzheimer’s and Parkinson’s disease, are characterized by defects in protein processing (McAlary et al., 2020) resulting in protein misfolding (Soto, 2003; Parakh and Atkin, 2016; Prasad et al., 2019), mislocalization (Tyzack et al., 2019; Suk and Rousseaux, 2020), and inclusion formation in motor neurons (Soto, 2003; ; Jucker and Walker, 2018; Steinacker et al., 2019). Classical neuropathological hallmarks of ALS include ubiquitinated inclusions containing the disordered TDP-43 and FUS (Neumann et al., 2006; Mackenzie et al., 2010; Ikenaka et al., 2020) proteins, although pathology can be heterogeneous with the appearance of other protein aggregates. Notably, recent research into ALS pathogenesis has implicated the partially disordered protein Matrin3 as playing a potentially significant role (Johnson et al., 2014; Malik et al., 2018; Ramesh et al., 2020; Malik and Barmada, 2021). Continued research into Matrin3’s structure and function will be critical to elucidating its interactions with other ALS proteins and nuanced role in the disease. Herein we consider the functional role of both the structured and disordered regions of Matrin3, with particular focus on the potential and documented role of disorder on aggregation and liquid-liquid phase separation (LLPS), as well as the profound effects that both mutation and post-translational modification have on Matrin3 behaviour as it relates to ALS pathogenicity.
Structure, Disorder, and LLPS in Matrin3
Matrin3 is a 125-kDa nuclear matrix protein encoded by the MATR3 gene located on chromosome 5 in humans. It is one of the twelve major inner nuclear matrix structural proteins that bind to the nuclear lamina and is ubiquitously expressed in almost all body tissues, with highest expression in brain (). Computational sequence- and structure-based analysis reveals the protein to be highly disordered (Figure 5, 1A/B), with AlphaFold2 (Jumper et al., 2021) predicting a largely unstructured protein with structure present almost exclusively in its four motifs: two RNA recognition motifs (RRM1 and RRM2) and two zinc-finger motifs (ZnF1 and ZnF2) (Figure 1B). The RRMs are comprised of four beta-strands and two alpha-helices arranged in a βαββαβ-fold (Figure 2A). Analysis of the AlphaFold2 structures of Matrin3, FUS and TDP-43 reveal significant structural homology among their RRMs, with FUS showing the largest deviations (Figure 2B). In Matrin3 the RRMs, in particular RRM2, are able to recognize and bind RNA (Salton et al., 2011; ), and this is one of the reasons why Matrin3 has been found to interact with other proteins involved in RNA processing (i.e., TDP-43, FUS and HNRNPA1).
FIGURE 1
FIGURE 2
Analysis of the association network of Matrin3 reveals many overlapping interactions with TDP-43 and FUS, further pointing to their similar functions in RNA regulation and ALS pathogenesis (Figure 3). The two Cys2His2 (C2H2) Zinc finger (ZnF) motifs in Matrin3 are highly similar (Figure 2E), both adopting a characteristic ββα-fold (Figure 2C), and are responsible for binding DNA and have been shown to facilitate protein interactions (; Iradi et al., 2018). The C2H2 ZnF differ from the ZnF found in FUS, namely a disordered RanBP2-type ZnF (Nguyen et al., 2011) that coordinates zinc via four cysteines (Figure 2D). Besides these four motifs, Matrin3 contains a carboxy-terminal nuclear localization signal (NLS) and an amino-terminal nuclear export signal (NES), that function as their names imply.
FIGURE 3
It is well established that the classical structure-function paradigm whereby an amino acid sequence defines one characteristic, stable, and well-folded protein with a unique biological function does not apply to many proteins, especially in the human proteome. The discovery of a large protein class, comprising both intrinsically disordered proteins (IDPs) that are almost entirely devoid of native structure, and proteins that contain both intrinsically disordered regions (IDRs) and well-structured motifs, has revealed that proteins can readily function as a conformational ensemble (; Uversky, 2019). These proteins often exhibit a high degree of spatial-temporal heterogeneity and conformational flexibility, with folding free energy landscapes that are relatively flat with a handful of shallow minima (Turoverov et al., 2010; Fisher and Stultz, 2011; Uversky, 2013a). This is a direct consequence of the enrichment of disorder-promoting amino acid residues over and above order-promoting ones within their sequences (Romero et al., 2001; Radivojac et al., 2007; Uversky, 2013b; Theillet et al., 2013). As a result of the flexibility introduced by these residues, IDP/IDRs are capable of interfacing with multiple binding partners via many interactions (Uversky, 2011; Oldfield and Dunker, 2014). While IDP/IDR binding can resemble an induced-fit or conformational selection mechanism (Mollica et al., 2016), IDP/IDRs are interaction specialists (Tompa et al., 2015), that as Uversky summarizes “are promiscuous binders that are never-nude” (Uversky, 2019). IDPs are almost always interacting with their binding partners, forming complexes of various types, including characteristic fuzzy complexes (Tompa and Fuxreiter, 2008; Khan et al., 2013; Sharma et al., 2015), and the strength of these interactions can range from transient and highly specific in signaling networks (Iakoucheva et al., 2002) to ultrahigh affinity interactions between oppositely charged proteins involved in chromatin condensation (). Particularly relevant to the discussion herein is the disordered nature of proteins implicated in ALS, in particular Matrin3. It is well documented that TDP-43 and FUS, both implicated in ALS, contain significant stretches of intrinsic disorder (Lin et al., 2017; Santamaria et al., 2017; ). Matrin3, a protein that has recently been shown to play a role in ALS pathogenesis, appears to be similarly disordered, which may be related to its pathogenicity.
Comparing the charge-hydropathy plots (Figure 4A), order-disorder residue (ODR) ratio (Figure 4B) and predicted disorder propensities (Figure 5, Supplementary Table S1) of Matrin3, TDP-43 and FUS reveals that Matrin3 is likely more disordered than TDP-43, but less disordered than FUS. Position-based analysis of Matrin3 disorder reveals that the region between RRM2 and ZnF2 have the highest tendency for disorder, while the region spanning the RRMs has the lowest. Considering the recent computational successes in describing the structural features and dynamics of disordered proteins (; Krzeminski et al., 2012; ; Ramis et al., 2019; Pietrek et al., 2020; Wilson et al., 2021a; ), molecular simulation of specific protein segments could help to more accurately characterize Matrin3, FUS, and TDP-43, by producing a structural ensemble rather than a single frame. Computational methods have also been extended to study protein aggregation propensities (Morriss-Andrews and Shea, 2015), liquid-liquid phase-separation (Paloni et al., 2020; ), IDP-protein interactions (; ; Karttunen et al., 2018), and the effects of mutation (Vacic et al., 2012; Wilson et al., 2021b) and post-translational modification (Jin and Graeter, 2021; Sieradzan et al., 2021) on protein structure, all potential avenues for investigation of a disordered ALS protein like Matrin3.
FIGURE 4
FIGURE 5
It has also been shown that many IDPs can undergo LLPS, and this biophysical phenomenon has emerged as a new paradigm underlying the intracellular assembly of proteins and other macromolecules, including RNA. LLPS is the reversible process of a homogenous fluid de-mixing into two distinct phases, a condensed phase and a dilute phase (Hyman et al., 2014; ; ). LLPS has been identified as a critical physical phenomenon underlying the formation of numerous membrane-less cellular organelles, such as P-bodies, stress granules and nucleoli (Kato et al., 2012; Molliex et al., 2015; Nott et al., 2015; Feric et al., 2016; ; ). In addition to membrane-less organelles, other structures can also be formed through LLPS, including transport channels in the nuclear pore complex (Su et al., 2016), and membrane receptor clusters at the cell membrane (Schmidt and Görlich, 2016).
Defects in LLPS have been speculated to drive protein misfolding and aggregation in different human diseases, including cataracts and neurodegenerative disorders like ALS (Patel et al., 2015; Wegmann et al., 2018; ; Pakravan et al., 2020; Watanabe et al., 2020; Zbinden et al., 2020). For example, proteins inside stress granules can undergo liquid-solid phase transition or can nucleate to form protein aggregates and this process can be accelerated by disease-causing mutations in ALS-associated genes. Specifically, ALS-causing mutations in the gene encoding FUS can result in drastic changes to the biophysical properties of the liquid droplets that form and induces the rapid formation of protein fibrils that are speculated to be cytotoxic (Patel et al., 2015). FUS contains a large intrinsically disordered prion-like domain (PrLD), with an ability to sample many conformational states that likely drives the formation of the liquid state.
These PrLDs, first discovered in yeast are rich in glycine and uncharged amino acids, resulting in a low order and a high degree of flexibility and solvent interaction. Many proteins containing PrLDs have been identified using hidden Markov algorithms (Lancaster et al., 2014; Harrison and Shorter, 2017), and proteomic surveys have revealed PrLDs to be particularly abundant in mammalian RNA-binding proteins (Hennig et al., 2015; Harrison and Shorter, 2017). In many cases, the RNA-binding proteins implicated in ALS (i.e., TDP-43, FUS, etc.) contain PrLDs that mediate their liquid-liquid phase separation. Interestingly, these regions are also where the majority of ALS-causing mutations occur (Gitler and Shorter, 2011; Harrison and Shorter, 2017).
Mutations in the PrLDs result in stark changes to the material properties of droplets formed by these proteins over time and stifle the reversibility of protein aggregate formation (Lin et al., 2015a; Kamps et al., 2021; Saar et al., 2021), leading to the sequestering of additional proteins within the aggregates (Watanabe et al., 2020).
By contrast, Matrin3 does not contain any PrLDs, yet it does contain large regions of disorder, and, similar to FUS, almost all of the ALS-associated amino acid substitutions (Figure 6A) and most of the documented post-translational modifications (Figure 6B) occur in Matrin3’s disordered regions. Matrin3 also undergoes liquid-liquid phase separation, and previous work has shown that the N-terminal region (300 amino acids) is required to mediate the phase separation of Matrin3 (Gallego-Iradi et al., 2019). Furthermore, the ALS causing mutation S85C appears to inhibit Matrin3 droplet formation, while P154S and F115C (now no longer considered an ALS-associated Matrin3 variant) do not (Malik et al., 2018; Gallego-Iradi et al., 2019). Furthermore, computational analysis using CamSol and Aggrescan3D, reveals that a significant proportion of the “highly insoluble” and aggregation-promoting residues in Matrin3 are localized to the disordered regions, in particular the N-terminus (Supplementary Figure S1). We therefore speculate that the intrinsically disordered regions of Matrin3 may not only drive its phase-separation behaviour but also promote its ALS-associated misfolding and aggregation.
FIGURE 6
Matrin3 Functions and Interactions
As discussed previously, intrinsically disordered proteins are highly flexible, endowing them with the potential to interact with a wide range of binding targets (Uversky, 2019; Oldfield and Dunker, 2014; Uversky, 2011). The regions of IDPs involved in productive binding within a complex are often structurally ill-defined and rarely exist in a single state (Sharma et al., 2015; Khan et al., 2013; Tompa and Fuxreiter, 2008; Freiberger et al., 2021; ). Although this flexibility may suggest that IDPs form extensive complementarity with their binding partners, IDPs often favor a T-shaped π−π geometry during protein-protein interactions, implying they deviate from stringent geometric complementarity (Tompa and Fuxreiter, 2008; Espinoza-Fonseca, 2012; Song et al., 2013; Moreira et al., 2013). This lack of complementarity has been linked to function, as it allows for IDPs to interact with many different binding partners. IDPs can interact with their partners through several binding modes, including polymorphic, clamp, flanking and random (Sharma et al., 2015; Tompa and Fuxreiter, 2008). It has been proposed that these alternative modes of binding give rise to the functional promiscuity observed in IDPs often allowing them to act as hubs in protein interactomes (Tompa et al., 2005; ; Haynes et al., 2006; Hu et al., 2017). Directed studies and unbiased proteome- and transcriptome-wide analyses have shown that Matrin3 interacts with DNA, RNA, and a diverse array of proteins, including the ALS-associated RNA-binding proteins TDP-43 () and FUS (Yamaguchi and Takanashi, 2016). Analysis of Matrin3’s association network reveals many overlapping binding partners with both proteins, highlighting the interdependence and connectivity between this trio, and further implicating Matrin3’s role in ALS pathogenesis (Figure 3). We note that Matrin3 is, however, unique among ALS-associated RNA binding proteins, as it possesses two tandem RRMS in addition to two ZnF motifs (i.e., FUS contains only one RRM and one zinc finger, and TDP-43 contains two RRMs and one N-terminal DNA binding motif). This collection of four motifs furnishes Matrin3 with the ability to readily interact with both DNA and RNA. One particular interaction involves the repression of exons by binding to the intronic regions of RNAs with pyrimidine-rich consensus sequences (Uemura et al., 2017). Interestingly, removal of one or both RRMs appears to have no effect on Matrin3 over-expression toxicity, while deletion of ZnF2 is significantly mitigating. This suggests that aberrant overbinding of DNA may be partially responsible for the neurodegenerative effects observed in neurons. This is further supported by observations that deletion of RRM2 is sufficient to promote the formation of phase-separated droplets; a result implying that RNA may prevent or reduce Matrin3 self association (Malik et al., 2018). Here we seek to briefly summarize some of the specific interactions of Matrin3 with RNA and DNA facilitated by its functional domains.
Binding and Stabilizing mRNA
Matrin3 contains two RRMs, and unsurprisingly has been shown to interact with RNA. Protein-RNA interaction analysis revealed Matrin3 directly interacts with four small noncoding RNAs, and genetic clustering showed 77 genes with reduced expression levels in MATR3-depleted cells (Salton et al., 2011). Furthermore, analysis of direct interaction between Matrin3 and mRNAs revealed not only that deletion of RRM2 neutered RNA-association, but that Matrin3 depletion resulted in a decrease in mRNA half-life, suggesting a transcript-stabilizing role for Matrin3 (Salton et al., 2011). Notably, Matrin3 interactions with RNA appear to facilitate associations with other RNA interacting proteins, specifically DHX9, implicated in transport (Tang et al., 1997) and translation of RNAs (Hartman et al., 2006), and HNRNPK, implicated in transcription, splicing, and translation (Moumen et al., 2005). In both cases, association between Matrin3 and these proteins is RNA-dependent.
Regulation of Alternative Splicing
Alternative splicing of mRNA is a highly regulated and crucial process that enables the expression of multiple proteins from a single mRNA transcript. This is facilitated through the interactions between repressor and enhancer proteins acting on the pre-mRNA (). Matrin3 is a strong regulator of splicing events as evidenced by Matrin3 knockdown-dependent dysregulation of 667 alterative splicing events and iCLIP analysis that revealed direct binding of Matrin3 to introns flanking repressed exons (). Matrin3’s splicing map is consistent with a mechanism whereby initial binding of Matrin3 at specific sites nucleates a cascade of binding across a long RNA region, culminating in repression of the targeted exon. The function of Matrin3 in exon inclusion is less clear. One possibility is that Matrin3 antagonizes the activity of another protein, namely polypyrimidine tract binding (PTB) protein, via interaction with Matrin3’s PTB-RRM interaction motif. PTB functions to repress exons and opposition of PTB function by Matrin3 could counteract this, facilitating inclusion ().
Regulation of Chromosomal Distribution
Nuclear matrix proteins (NMP) bind DNA at multiple sites in the genome, and Matrin3 is a highly abundant NMP identified in the inner nuclear matrix (Nakayasu and Berezney, 1991). Minimum-spanning tree (MST) algorithms (Dusser et al., 1987; Dussert et al., 1988; Malyavantham et al., 2008) and 3D fluorescence in situ hybridization (FISH) (Langer-Safer et al., 1982) indicated that Matrin3 localizes to extra-nucleolar regions of the nucleus and to relatively distinct sites.
Line profile analysis revealed that Matrin3 was associated with regions in both the gene-poor chromosome 18 and gene-rich chromosome 19 (Zeitz et al., 2009). Analysis using three-dimensional edge detection indicated that Matrin3 was absent from both the perinuclear and perinucleolar heterochromatin and from the inactive copy of the X chromosome but not the active X chromosome, suggesting a possible role in euchromatin organization and function (Zeitz et al., 2009).
DNA Damage Repair
The DNA damage response is an intricate cellular cascade that is activated in response to DNA damage. One of the most potent activators of the DNA damage response is DNA double-strand breaks (DSBs) (Jackson and Bartek, 2009), and ataxia telangiectasia mutated (ATM) is one of the major nuclear kinases that mediates this response (Khanna et al., 2001). Following the recruitment of ATM to DSB sites, the kinase phosphorylates effector proteins in different response pathways (Marechal and Zou, 2013). Matrin3 is an ATM target as serine 208, located in the disordered N-terminus of Martin3, is phosphorylated following DNA damage (Salton et al., 2010; Niimori-Kita et al., 2018). Matrin3 has also been implicated in the nuclear retention of hyper-edited RNA together with NONO/SFPQ. Matrin3, SFPQ, and NONO may associate with major non-homologous end-joining proteins forming a large hetero-complex and further implicating Matrin3 in DSB response (; Rajesh et al., 2009; Salton et al., 2010). These results imply that Matrin3 is involved in initiating and carrying out DNA damage response. While the precise mechanism underlying this is not fully understood, it is reasonable to speculate that the disordered nature of Matrin3 facilitates its synergistic interactions with multiple targets in a phospho-dependent manner and might act as a scaffold for the hetero-complex.
Matrin3 Disease Variants and Pathology
Mutations in the intrinsically disordered regions of protein can drive disease phenotypes by perturbing existing structures (Vacic et al., 2012; Schrag et al., 2021), inducing the formation of novel structural motifs (; Meyer et al., 2018), altering protein-protein interactions (Wong et al., 2020) and promoting self-interaction (Lim et al., 2016), to name a few.
Analysis of two well documented ALS-associated proteins, TDP-43 and FUS, reveals a clustering of disease-producing mutations in their disordered, prion-like domains. Analysis of Matrin3 reveals a similar trend, where previously reported ALS-substitutions are spread across the protein, yet cluster in disordered regions (Figure 6A, Supplementary Table S3). Previous work has documented that mutations in Matrin3 give rise to distinct disease phenotypes, including familial ALS, frontotemporal dementia (FTD), and hereditary distal myopathy (Senderek et al., 2009; Johnson et al., 2014; Millecamps et al., 2014; Lin et al., 2015b; Origone et al., 2015; Leblond et al., 2016; Xu et al., 2016; Marangi et al., 2017). While significant variation is present in the IDRs of Matrin3, only a subset of these variants are documented or predicted to be pathogenic. Why it is that seemingly identical IDR mutations in a protein can give rise to different phenotypes is the focus of much study. Although IDPs lack a fixed 3D structure in their unbound state, when interacting with a binding partner, IDPs can adopt a more structured conformation (). IDPs can also tolerate mutations in their binding partners that result in increased conformational dynamics, where the IDP adapts to the perturbation in the partner and maintains complementarity at the interface (Huang and Liu, 2013; Mesrouze et al., 2018). The opposite may also be true; increased conformational flexibility, induced by mutation within IDRs, may be readily tolerated and could account for the many non-pathological mutations observed in the IDRs of Matrin3. It is also possible that a single or several mutations could sufficiently perturb the local conformation of a protein, exceeding a flexibility threshold, resulting in a pathological phenotype. The lack of mutations seen in the structured motifs of Matrin3 suggests that, unlike the IDRs, these regions have a much lower “flexibility threshold” and are unable to accommodate most mutations that would severely distort the local conformation of the protein and lead to non-viable phenotypes.
We here note that the frequently reported F115C mutation is no longer believed to be implicated in fALS. While this was one of the first documented mutations alleged to have been causal of fALS (Johnson et al., 2014), recent reanalysis of the kindred studied in the original work revealed that another protein mutation was responsible (Saez-Atienzar et al., 2020). This finding was supported by results observed in an earlier mouse study (Malik et al., 2018). Interestingly, F115C nevertheless results in abundant nuclear inclusions of Matrin3 (Gallego-Iradi et al., 2015). This differs from the S85C mutation, which results in mislocalized Matrin3 that co-aggregates with TDP-43 in the cytosol (Johnson et al., 2014). Notably, even in patients without any disease-producing MATR3 mutations, mislocalization of Matrin3 has been observed in fALS cases () (i.e., patients with fALS caused by C9orf72 repeat expansion (Johnson et al., 2014)), and in patients with sALS (Tada et al., 2018). Phenotypic variability as a result of mutation is also evident in carriers of the S707L variant, who present with cognitive and behavioral features, suggesting a co-pathology of both ALS and FTD (Marangi et al., 2017). In total there are 49 documented MATR3 variants observed in patients presenting with both sporadic and familial ALS/FTD (Figure 6, Supplementary Table S2).
Recently, the NIH-funded Clinical Genome Resource (ClinGen) published a standard framework for the evaluation of gene-disease correlations, and efforts are ongoing to classify gene associations across many diseases by Gene Curation Expert Panels (GCEPs), including ALS (Strande et al., 2017). The curation of MATR3 was recently completed and the gene-disease was given a classification of “Moderate” based on a review of variants previously reported in ALS cases and relevant experimental evidence. This classification indicates that while there is evidence to support a causal role for MATR3 in ALS and there is no convincing contradictions to the relationship, further evidence is required to attain a “Strong” or “Definitive” classification. In the case of MATR3, the ALS GCEP recommends that further functional analyses of potentially pathogenic variants are performed to increase the confidence in the gene-disease relationship.
Matrin3 Post-translational Modifications
Post-translational modifications, including phosphorylation, ubiquitination and acetylation, readily occur in, and alter, the conformation of disordered proteins (van der Lee et al., 2014; ; Wright and Dyson, 2015; ; ; Iakoucheva et al., 2004), increase LLPS potential (Hofweber and Dormann, 2019; Rhoads et al., 2018; Owen and Shewmaker, 2019), and modulate aggregation (Funk et al., 2014; Furukawa et al., 2008; Ercan-Herbst et al., 2019; Schaffert and Carter, 2020). As with the disordered TDP-43 and FUS, post-translational modification of Matrin3 is relatively constrained to its disordered regions with some modifications occurring in RRM2 and ZnF2 (Figure 6B, Supplementary Table S4). Aberrant phosphorylation in TDP-43 has been shown to result in increased cytoplasmic mislocalization and aggregation in neuronal cells (Prasad et al., 2019), and multi-site phosphorylated TDP-43 inclusions in the brain is a hallmark of ALS (Neumann et al., 2007; Hasegawa et al., 2008). Also, FUS phosphorylation tempers its aggregation-prone behaviour and disrupts its ability to undergo phase separation in the presence of RNA (Monahan et al., 2017). Matrin3 is also a phosphoprotein with multiple phosphorylation sites for tyrosine and serine/threonine kinases (Hibino et al., 1998). Three different protein kinases have been identified that phosphorylate Matrin3, ATM kinase, pyruvate kinase M2 (PKM2) and cAMP-dependent protein kinase (PKA). ATM kinase phosphorylates Matrin3 at S208 in response to DNA double-stranded breaks activating DNA damage repair response (Salton et al., 2010); PKM2 modifies the protein at T239, inhibiting degradation by preventing K48-linked ubiquitination (Kumari and Das, 2019); and PKA phosphorylates S188 in response to NMDA receptor activation and its inhibition prevents phosphorylation and degradation of Matrin3 and neuronal death (Giordano et al., 2005).
Ubiquitin is a highly conserved 76 amino acid protein that is expressed in all eukaryotic cells and can be enzymatically linked to lysine residues of target proteins (Pickart, 2001). Pathological protein inclusions are frequently ubiquitin-positive. Indeed, both TDP-43 and FUS have been found as components in ubiquitin-positive inclusions, characteristic of FTD and ALS (; Neumann et al., 2007; Farrawell et al., 2015). The role of ubiquitination in Matrin3 mislocalization and accumulation in ALS remains to be determined.
Lysine acetylation is another major post-translational modification that regulates the functions of many proteins (). Large-scale proteomic studies have identified ∼ 1750 proteins as substrates for lysine acetylation, including RNA-binding proteins involved in ALS (; ). Specifically, acetylation of the RRMs in TDP-43, can impair RNA binding that results in the accumulation of insoluble, hyper-phosphorylated TDP-43 species; these have pathological similarities to those observed in FTD (). Furthermore, FUS has recently been shown to be acetylated in both its nuclear localization sequence and RRM resulting in mislocalization and decreased aggregation, respectively (). Matrin3 contains many predicted lysine acetylation sites positioned throughout its structured and disordered regions, suggesting that acetylation may play a role in ALS pathogenesis.
In sum, it is evident that post-translational modifications can modulate LLPS and protein aggregation of the ALS proteins TDP-43 and FUS, yet their exact role in Matrin3 pathology remains to be clarified.
Conclusion
Herein, we summarize findings documenting the role that Matrin3 plays in both fALS and sALS in the context of its intrinsically disordered regions, mutations, and post-translational modifications. We discuss how these disordered regions may contribute to its misfolding, resulting in pathological accumulation and mislocalization and ultimately contributing to ALS pathogenesis. Evidently, there are many important questions that future research will need to address to fully decipher the role of Matrin3 in ALS. Does Matrin3 misfolding contribute to ALS by a gain of toxic function, or a loss of function mechanisms, or a mixture of both? What triggers the intrinsically disordered domains of Matrin3 to misfold and how is Matrin3 misfolding typically prevented by cellular protein quality control? How do the pathological variants of Matrin3 contribute to misfolding, and what protein interactions may they alter? And how do the interactions with other ALS-associated proteins, such as TDP43 and FUS, and many other proteins, alter Matrin3 misfolding and mislocalization? As discussed previously, Matrin3 lacks the PrLDs present in TDP-43 and FUS which mediates their liquid-liquid phase separation. Therefore, it is important to determine what separates Matrin3 from the majority of other IDPs in the human proteome that are not linked with pathological misfolding. Detailed structural investigations, computational analyses, and new effective cellular and animal models together, will help to advance our understanding of the role of Matrin3 in ALS pathogenesis and, more generally, will elucidate how intrinsically disordered proteins and intrinsically disordered regions contribute to protein misfolding in neurodegenerative diseases.
Statements
Author contributions
AS and MD conceived of the review; AS drafted the original manuscript; CW drafted the revised manuscript; AS, CW, BR, AD, and SF collected data for analysis and table generation; CW and AD generated figures; All authors read, edited, and approved the submitted version.
Acknowledgments
The authors thank the Natural Sciences and Engineering Research Council of Canada (NSERC) and the Canadian Institutes of Health Research (CIHR) for funding. MD also thanks ALS Canada for financial support.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmolb.2021.794646/full#supplementary-material
References
1
AbeK.AokiM.TsujiS.ItoyamaY.SobueG.TogoM.et al (2017). Safety and Efficacy of Edaravone in Well Defined Patients with Amyotrophic Lateral Sclerosis: a Randomised, Double-Blind, Placebo-Controlled Trial. Lancet Neurol.16, 505–512. 10.1016/s1474-4422(17)30115-1
2
AlbertiS.DormannD. (2019). Liquid-Liquid Phase Separation in Disease. Annu. Rev. Genet.53, 171–194. 10.1146/annurev-genet-112618-043527
3
AliI.ConradR. J.VerdinE.OttM. (2018). Lysine Acetylation Goes Global: From Epigenetics to Metabolism and Therapeutics. Chem. Rev.118, 1216–1252. 10.1021/acs.chemrev.7b00181
4
AndrewsJ. A.JacksonC. E.Heiman-PattersonT. D.BetticaP.BrooksB. R.PioroE. P. (2020). Real-world Evidence of Riluzole Effectiveness in Treating Amyotrophic Lateral Sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degeneration21, 509–518. 10.1080/21678421.2020.1771734
5
AraiT.HasegawaM.AkiyamaH.IkedaK.NonakaT.MoriH.et al (2006). TDP-43 Is a Component of Ubiquitin-Positive Tau-Negative Inclusions in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Biochem. Biophysical Res. Commun.351, 602–611. 10.1016/j.bbrc.2006.10.093
6
ArbesúM.IruelaG.FuentesH.TeixeiraJ. M. C.PonsM. (2018). Intramolecular Fuzzy Interactions Involving Intrinsically Disordered Domains. Front. Mol. Biosci.5, 39. 10.3389/fmolb.2018.00039
7
ArenasA.ChenJ.KuangL.BarnettK. R.KasarskisE. J.GalJ.et al (2020). Lysine Acetylation Regulates the RNA Binding, Subcellular Localization and Inclusion Formation of FUS. Hum. Mol. Genet.29, 2684–2697. 10.1093/hmg/ddaa159
8
BahA.Forman-KayJ. D. (2016). Modulation of Intrinsically Disordered Protein Function by Post-translational Modifications. J. Biol. Chem.291, 6696–6705. 10.1074/jbc.R115.695056
9
BahA.VernonR. M.SiddiquiZ.KrzeminskiM.MuhandiramR.ZhaoC.et al (2015). Folding of an Intrinsically Disordered Protein by Phosphorylation as a Regulatory Switch. Nature519, 106–109. 10.1038/nature13999
10
BananiS. F.LeeH. O.HymanA. A.RosenM. K. (2017). Biomolecular Condensates: Organizers of Cellular Biochemistry. Nat. Rev. Mol. Cel Biol.18, 285–298. 10.1038/nrm.2017.7
11
BenayadZ.von BülowS.StelzlL. S.HummerG. (2021). Simulation of FUS Protein Condensates with an Adapted Coarse-Grained Model. J. Chem. Theor. Comput.17, 525–537. 10.1021/acs.jctc.0c01064
12
BensimonG.LacomblezL.MeiningerV. (1994). A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis. N. Engl. J. Med.330, 585–591. 10.1056/nejm199403033300901
13
BladenC. L.UdayakumarD.TakedaY.DynanW. S. (2005). Identification of the Polypyrimidine Tract Binding Protein-Associated Splicing Factor·p54(nrb) Complex as a Candidate DNA Double-Strand Break Rejoining Factor. J. Biol. Chem.280, 5205–5210. 10.1074/jbc.m412758200
14
BlokhuisA. M.GroenE. J. N.KoppersM.van den BergL. H.PasterkampR. J. (2013). Protein Aggregation in Amyotrophic Lateral Sclerosis. Acta Neuropathol.125, 777–794. 10.1007/s00401-013-1125-6
15
BlumM.ChangH.-Y.ChuguranskyS.GregoT.KandasaamyS.MitchellA.et al (2020). The InterPro Protein Families and Domains Database: 20 Years on. Nucleic Acids Res.49, D344–D354. 10.1093/nar/gkaa977
16
BoehringerR.PolygalovD.HuangA. J. Y.MiddletonS. J.RobertV.WintzerM. E.et al (2017). Chronic Loss of CA2 Transmission Leads to Hippocampal Hyperexcitability. Neuron94, 642–655.e9. 10.1016/j.neuron.2017.04.014
17
BoeynaemsS.AlbertiS.FawziN. L.MittagT.PolymenidouM.RousseauF.et al (2018). Protein Phase Separation: A New Phase in Cell Biology. Trends Cel Biol.28, 420–435. 10.1016/j.tcb.2018.02.004
18
BorgiaA.BorgiaM. B.BuggeK.KisslingV. M.HeidarssonP. O.FernandesC. B.et al (2018). Extreme Disorder in an Ultrahigh-Affinity Protein Complex. Nature555, 61–66. 10.1038/nature25762
19
BrayerK. J.SegalD. J. (2008). Keep Your Fingers off My DNA: Protein-Protein Interactions Mediated by C2H2 Zinc Finger Domains. Cell Biochem. Biophys.50, 111–131. 10.1007/s12013-008-9008-5
20
BuchanD. W. A.JonesD. T. (2019). The PSIPRED Protein Analysis Workbench: 20 Years on. Nucleic Acids Res.47, W402–W407. 10.1093/nar/gkz297
21
ChangM.WilsonC. J.KarunatillekeN. C.MoselhyM. H.KarttunenM.ChoyW.-Y. (2021). Exploring the Conformational Landscape of the Neh4 and Neh5 Domains of Nrf2 Using Two Different Force Fields and Circular Dichroism. J. Chem. Theor. Comput.17, 3145–3156. 10.1021/acs.jctc.0c01243
22
ChenH.RichardM.SandlerD. P.UmbachD. M.KamelF. (2007). Head Injury and Amyotrophic Lateral Sclerosis. Am. J. Epidemiol.166, 810–816. 10.1093/aje/kwm153
23
ChenM.ManleyJ. L. (2009). Mechanisms of Alternative Splicing Regulation: Insights from Molecular and Genomics Approaches. Nat. Rev. Mol. Cel Biol.10, 741–754. 10.1038/nrm2777
24
ChiangW. C.LeeM. H.ChenT. C.HuangJ. R. (2020). Interactions between the Intrinsically Disordered Regions of hnRNP-A2 and TDP-43 Accelerate TDP-43's Conformational Transition. Int. J. Mol. Sci.21, 21. 10.3390/ijms21165930
25
ChoiJ.-M.HolehouseA. S.PappuR. V. (2020). Physical Principles Underlying the Complex Biology of Intracellular Phase Transitions. Annu. Rev. Biophys.49, 107–133. 10.1146/annurev-biophys-121219-081629
26
CinoE. A.KilloranR. C.KarttunenM.ChoyW. Y. (2013). Binding of Disordered Proteins to a Protein Hub. Sci. Rep.3, 2305. 10.1038/srep02305
27
CinoE. A.Wong-ekkabutJ.KarttunenM.ChoyW. Y. (2011). Microsecond Molecular Dynamics Simulations of Intrinsically Disordered Proteins Involved in the Oxidative Stress Response. PLOS ONE6, e27371–13. 10.1371/journal.pone.0027371
28
CoelhoM. B.AttigJ.BelloraN.KönigJ.HalleggerM.KayikciM.et al (2015). Nuclear Matrix Protein Matrin3 Regulates Alternative Splicing and Forms Overlapping Regulatory Networks with PTB. EMBO J.34, 653–668. 10.15252/embj.201489852
29
CoelhoM. B.AttigJ.UleJ.SmithC. W. J. (2016). Matrin3: Connecting Gene Expression with the Nuclear Matrix. WIREs RNA7, 303–315. 10.1002/wrna.1336
30
CohenT. J.HwangA. W.RestrepoC. R.YuanC. X.TrojanowskiJ. Q.LeeV. M. (2015). An Acetylation Switch Controls TDP-43 Function and Aggregation Propensity. Nat. Commun.6, 5845. 10.1038/ncomms6845
31
ConicellaA. E.DignonG. L.ZerzeG. H.SchmidtH. B.D’OrdineA. M.KimY. C.et al (2020). TDP-43 α-helical Structure Tunes Liquid-Liquid Phase Separation and Function. Proc. Natl. Acad. Sci. USA117, 5883–5894. 10.1073/pnas.1912055117
32
CsizmokV.Forman-KayJ. D. (2018). Complex Regulatory Mechanisms Mediated by the Interplay of Multiple post-translational Modifications. Curr. Opin. Struct. Biol.48, 58–67. 10.1016/j.sbi.2017.10.013
33
DarlingA. L.UverskyV. N. (2018). Intrinsic Disorder and Posttranslational Modifications: The Darker Side of the Biological Dark Matter. Front. Genet.9, 158. 10.3389/fgene.2018.00158
34
DeForteS.UverskyV. N. (2016). Intrinsically Disordered Proteins in PubMed: what Can the Tip of the Iceberg Tell Us about what Lies below?RSC Adv.6, 11513–11521. 10.1039/c5ra24866c
35
DoT. N.ChoyW.-Y.KarttunenM. (2014). Accelerating the Conformational Sampling of Intrinsically Disordered Proteins. J. Chem. Theor. Comput.10, 5081–5094. 10.1021/ct5004803
36
DoT. N.ChoyW.-Y.KarttunenM. (2016). Binding of Disordered Peptides to Kelch: Insights from Enhanced Sampling Simulations. J. Chem. Theor. Comput.12, 395–404. 10.1021/acs.jctc.5b00868
37
DobleA. (1996). The Pharmacology and Mechanism of Action of Riluzole. Neurology47, 233S–241S. 10.1212/wnl.47.6_suppl_4.233s
38
DoganJ.GianniS.JemthP. (2014). The Binding Mechanisms of Intrinsically Disordered Proteins. Phys. Chem. Chem. Phys.16, 6323–6331. 10.1039/c3cp54226b
39
DreserA.VollrathJ. T.SechiA.JohannS.RoosA.YamoahA.et al (2017). The ALS-Linked E102Q Mutation in Sigma Receptor-1 Leads to ER Stress-Mediated Defects in Protein Homeostasis and Dysregulation of RNA-Binding Proteins. Cell Death Differ24, 1655–1671. 10.1038/cdd.2017.88
40
DunkerA. K.CorteseM. S.RomeroP.IakouchevaL. M.UverskyV. N. (2005). Flexible Nets. The Roles of Intrinsic Disorder in Protein Interaction Networks. FEBS J.272, 5129–5148. 10.1111/j.1742-4658.2005.04948.x
41
DusserC.RasigniM.PalmariJ.RasigniG.LlebariaA.MartyF. (1987). Minimal Spanning Tree Analysis of Biological Structures. J. Theor. Biol.125, 317–323. 10.1016/s0022-5193(87)80063-2
42
DussertC.RasigniG.LlebariaA. (1988). Quantization of Directional Properties in Biological Structures Using the Minimal Spanning Tree. J. Theor. Biol.135, 295–302. 10.1016/s0022-5193(88)80245-5
43
Ercan-HerbstE.EhrigJ.SchöndorfD. C.BehrendtA.KlausB.Gomez RamosB.et al (2019). A post-translational Modification Signature Defines Changes in Soluble Tau Correlating with Oligomerization in Early Stage Alzheimer's Disease Brain. Acta Neuropathol. Commun.7, 192. 10.1186/s40478-019-0823-2
44
Espinoza-FonsecaL. M. (2012). Aromatic Residues Link Binding and Function of Intrinsically Disordered Proteins. Mol. Biosyst.8, 237–246. 10.1039/c1mb05239j
45
FarhanS. M. K.HowriganD. P.HowriganD. P.AbbottL. E.KlimJ. R.ToppS. D.et al (2019). Exome Sequencing in Amyotrophic Lateral Sclerosis Implicates a Novel Gene, DNAJC7, Encoding a Heat-Shock Protein. Nat. Neurosci.22, 1966–1974. 10.1038/s41593-019-0530-0
46
FarrawellN. E.Lambert-SmithI. A.WarraichS. T.BlairI. P.SaundersD. N.HattersD. M.et al (2015). Distinct Partitioning of ALS Associated TDP-43, FUS and SOD1 Mutants into Cellular Inclusions. Sci. Rep.5, 13416. 10.1038/srep13416
47
FericM.VaidyaN.HarmonT. S.MitreaD. M.ZhuL.RichardsonT. M.et al (2016). Coexisting Liquid Phases Underlie Nucleolar Subcompartments. Cell165, 1686–1697. 10.1016/j.cell.2016.04.047
48
FisherC. K.StultzC. M. (2011). Constructing Ensembles for Intrinsically Disordered Proteins. Curr. Opin. Struct. Biol.21, 426–431. 10.1016/j.sbi.2011.04.001
49
ForanE.TrottiD. (2009). Glutamate Transporters and the Excitotoxic Path to Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis. Antioxid. Redox Signaling11, 1587–1602. 10.1089/ars.2009.2444
50
FreibergerM. I.WolynesP. G.FerreiroD. U.FuxreiterM. (2021). Frustration in Fuzzy Protein Complexes Leads to Interaction Versatility. J. Phys. Chem. B125, 2513–2520. 10.1021/acs.jpcb.0c11068
51
FunkK. E.ThomasS. N.SchaferK. N.CooperG. L.LiaoZ.ClarkD. J.et al (2014). Lysine Methylation Is an Endogenous post-translational Modification of Tau Protein in Human Brain and a Modulator of Aggregation Propensity. Biochem. J.462, 77–88. 10.1042/bj20140372
52
FurukawaY.KanekoK.YamanakaK.O'HalloranT. V.NukinaN. (2008). Complete Loss of Post-translational Modifications Triggers Fibrillar Aggregation of SOD1 in the Familial Form of Amyotrophic Lateral Sclerosis. J. Biol. Chem.283, 24167–24176. 10.1074/jbc.M802083200
53
Gallego-IradiM. C.ClareA. M.BrownH. H.JanusC.LewisJ.BorcheltD. R. (2015). Subcellular Localization of Matrin 3 Containing Mutations Associated with ALS and Distal Myopathy. PLOS ONE10, e0142144–15. 10.1371/journal.pone.0142144
54
Gallego-IradiM. C.StrunkH.CrownA. M.DavilaR.BrownH.Rodriguez-LebronE.et al (2019). N-terminal Sequences in Matrin 3 Mediate Phase Separation into Droplet-like Structures that Recruit TDP43 Variants Lacking RNA Binding Elements. Lab. Invest.99, 1030–1040. 10.1038/s41374-019-0260-7
55
GiordanoG.Sánchez-PérezA. M.MontoliuC.BerezneyR.MalyavanthamK.CostaL. G.et al (2005). Activation of NMDA Receptors Induces Protein Kinase A-Mediated Phosphorylation and Degradation of Matrin 3. Blocking These Effects Prevents NMDA-Induced Neuronal Death. J. Neurochem.94, 808–818. 10.1111/j.1471-4159.2005.03235.x
56
GitlerA. D.ShorterJ. (2011). RNA-binding Proteins with Prion-like Domains in ALS and FTLD-U. Prion5, 179–187. 10.4161/pri.5.3.17230
57
HarrisonA. F.ShorterJ. (2017). RNA-binding Proteins with Prion-like Domains in Health and Disease. Biochem. J.474, 1417–1438. 10.1042/bcj20160499
58
HartmanT. R.QianS.BolingerC.FernandezS.SchoenbergD. R.Boris-LawrieK. (2006). RNA Helicase A Is Necessary for Translation of Selected Messenger RNAs. Nat. Struct. Mol. Biol.13, 509–516. 10.1038/nsmb1092
59
HasegawaM.AraiT.NonakaT.KametaniF.YoshidaM.HashizumeY.et al (2008). Phosphorylated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Ann. Neurol.64, 60–70. 10.1002/ana.21425
60
HaynesC.OldfieldC. J.JiF.KlitgordN.CusickM. E.RadivojacP.et al (2006). Intrinsic Disorder Is a Common Feature of Hub Proteins from Four Eukaryotic Interactomes. PLOS Comput. Biol.2, e100–12. 10.1371/journal.pcbi.0020100
61
HennigS.KongG.MannenT.SadowskaA.KobelkeS.BlytheA.et al (2015). Prion-like Domains in RNA Binding Proteins Are Essential for Building Subnuclear Paraspeckles. J. Cel Biol.210, 529–539. 10.1083/jcb.201504117
62
HibinoY.OhzekiH.HiroseN.SuganoN. (1998). Involvement of Phosphorylation in Binding of Nuclear Scaffold Proteins from Rat Liver to a Highly Repetitive DNA Component. Biochim. Biophys. Acta1396, 88–96. 10.1016/s0167-4781(97)00176-0
63
HofweberM.DormannD. (2019). Friend or foe-Post-translational Modifications as Regulators of Phase Separation and RNP Granule Dynamics. J. Biol. Chem.294, 7137–7150. 10.1074/jbc.TM118.001189
64
HornbeckP. V.ZhangB.MurrayB.KornhauserJ. M.LathamV.SkrzypekE. (2014). PhosphoSitePlus, 2014: Mutations, PTMs and Recalibrations. Nucleic Acids Res.43, D512–D520. 10.1093/nar/gku1267
65
HuG.WuZ.UverskyV. N.KurganL. (2017). Functional Analysis of Human Hub Proteins and Their Interactors Involved in the Intrinsic Disorder-Enriched Interactions. Int. J. Mol. Sci.18. 10.3390/ijms18122761
66
HuangY.LiuZ. (2013). Do Intrinsically Disordered Proteins Possess High Specificity in Protein-Protein Interactions?Chem. Eur. J.19, 4462–4467. 10.1002/chem.201203100
67
HymanA. A.WeberC. A.JülicherF. (2014). Liquid-Liquid Phase Separation in Biology. Annu. Rev. Cel Dev. Biol.30, 39–58. 10.1146/annurev-cellbio-100913-013325
68
IakouchevaL. M.BrownC. J.LawsonJ. D.ObradovićZ.DunkerA. K. (2002). Intrinsic Disorder in Cell-Signaling and Cancer-Associated Proteins. J. Mol. Biol.323, 573–584. 10.1016/s0022-2836(02)00969-5
69
IakouchevaL. M.RadivojacP.BrownC. J.O’ConnorT. R.SikesJ. G.ObradovicZ.et al (2004). The Importance of Intrinsic Disorder for Protein Phosphorylation. Nucleic Acids Res.32, 1037–1049. 10.1093/nar/gkh253
70
IkenakaK.IshigakiS.IguchiY.KawaiK.FujiokaY.YokoiS.et al (2020). Characteristic Features of FUS Inclusions in Spinal Motor Neurons of Sporadic Amyotrophic Lateral Sclerosis. J. Neuropathol. Exp. Neurol.79, 370–377. 10.1093/jnen/nlaa003
71
IngreC.RoosP. M.PiehlF.KamelF.FangF. (2015). Risk Factors for Amyotrophic Lateral Sclerosis. Clin. Epidemiol.7, 181–193. 10.2147/CLEP.S37505
72
IradiM. C. G.TriplettJ. C.ThomasJ. D.DavilaR.CrownA. M.BrownH.et al (2018). Characterization of Gene Regulation and Protein Interaction Networks for Matrin 3 Encoding Mutations Linked to Amyotrophic Lateral Sclerosis and Myopathy. Sci. Rep.8, 4049. 10.1038/s41598-018-21371-4
73
JacksonS. P.BartekJ. (2009). The DNA-Damage Response in Human Biology and Disease. Nature461, 1071–1078. 10.1038/nature08467
74
JaiswalM. K.ZechW.-D.GoosM.LeutbecherC.FerriA.ZippeliusA.et al (2006). Riluzole but Not Melatonin Ameliorates Acute Motor Neuron Degeneration and Moderately Inhibits SOD1-Mediated Excitotoxicity Induced Disrupted Mitochondrial Ca2+ Signaling in Amyotrophic Lateral Sclerosis. Front Cel Neurosci10, 295. 10.3389/fncel.2016.00295
75
JaiswalM. K. (2019). Riluzole and Edaravone: A Tale of Two Amyotrophic Lateral Sclerosis Drugs. Med. Res. Rev.39, 733–748. 10.1002/med.21528
76
JaiswalM. K. (2017). Riluzole but Not Melatonin Ameliorates Acute Motor Neuron Degeneration and Moderately Inhibits SOD1-Mediated Excitotoxicity Induced Disrupted Mitochondrial Ca2+ Signaling in Amyotrophic Lateral Sclerosis. Front. Cel. Neurosci.10, 295. 10.3389/fncel.2016.00295
77
JinF.Gr¨aterF. (2021). How Multisite Phosphorylation Impacts the Conformations of Intrinsically Disordered Proteins. PLOS Comput. Biol.17, 1–19. 10.1371/journal.pcbi.1008939
78
JohnsonJ. O.PioroE. P.PioroE. P.BoehringerA.ChiaR.FeitH.(2014). Mutations in the Matrin 3 Gene Cause Familial Amyotrophic Lateral Sclerosis. Nat. Neurosci.17, 664–666. 10.1038/nn.3688
79
JonesD. T.CozzettoD. (2014). DISOPRED3: Precise Disordered Region Predictions with Annotated Protein-Binding Activity. Bioinformatics31, 857–863. 10.1093/bioinformatics/btu744
80
JuckerM.WalkerL. C. (2018). Propagation and Spread of Pathogenic Protein Assemblies in Neurodegenerative Diseases. Nat. Neurosci.21, 1341–1349. 10.1038/s41593-018-0238-6
81
JumperJ.EvansR.PritzelA.GreenT.FigurnovM.RonnebergerO.et al (2021). Highly Accurate Protein Structure Prediction with AlphaFold. Nature596, 583–589. 10.1038/s41586-021-03819-2
82
KampsJ.LinY.-H.OlivaR.BaderV.WinterR.WinklhoferK. F.et al (2021). The N-Terminal Domain of the Prion Protein Is Required and Sufficient for Liquid-Liquid Phase Separation: A Crucial Role of the Aβ-Binding Domain. J. Biol. Chem.297, 100860. 10.1016/j.jbc.2021.100860
83
KarttunenM.ChoyW.-Y.CinoE. A. (2018). Prediction of Binding Energy of Keap1 Interaction Motifs in the Nrf2 Antioxidant Pathway and Design of Potential High-Affinity Peptides. J. Phys. Chem. B122, 5851–5859. 10.1021/acs.jpcb.8b03295
84
KatoM.HanT. W.XieS.ShiK.DuX.WuL. C.et al (2012). Cell-free Formation of RNA Granules: Low Complexity Sequence Domains Form Dynamic Fibers within Hydrogels. Cell149, 753–767. 10.1016/j.cell.2012.04.017
85
KhanH.CinoE. A.BrickendenA.FanJ.YangD.ChoyW.-Y. (2013). Fuzzy Complex Formation between the Intrinsically Disordered Prothymosin α and the Kelch Domain of Keap1 Involved in the Oxidative Stress Response. J. Mol. Biol.425, 1011–1027. 10.1016/j.jmb.2013.01.005
86
KhannaK.LavinM.JacksonS.MulhernT. (2001). ATM, a central Controller of Cellular Responses to DNA Damage. Cel Death Differ8, 1052–1065. 10.1038/sj.cdd.4400874
87
KiernanM. C.VucicS.CheahB. C.TurnerM. R.EisenA.HardimanO.et al (2011). Amyotrophic Lateral Sclerosis. Lancet377, 942–955. 10.1016/S0140-6736(10)61156-7
88
KrzeminskiM.MarshJ. A.NealeC.ChoyW.-Y.Forman-KayJ. D. (2012). Characterization of Disordered Proteins with ENSEMBLE. Bioinformatics29, 398–399. 10.1093/bioinformatics/bts701
89
KumariR.DasS. (2019). Abstract 2852: PKM2 Phosphorylates and Stabilises Matrin 3 Which Promotes FOXC2-Mediated Tumorigenesis. Cancer Res.79, 2852. 10.1158/1538-7445.am2019-2852
90
KurtzkeJ. F.BeebeG. W. (1980). Epidemiology of Amyotrophic Lateral Sclerosis: 1. A Case-Control Comparison Based on ALS Deaths. Neurology30, 453. 10.1212/wnl.30.5.453
91
KyteJ.DoolittleR. F. (1982). A Simple Method for Displaying the Hydropathic Character of a Protein. J. Mol. Biol.157, 105–132. 10.1016/0022-2836(82)90515-0
92
LacomblezL.BensimonG.BensimonG.MeiningerV.LeighP. N.GuilletP. (1996). Dose-ranging Study of Riluzole in Amyotrophic Lateral Sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. The Lancet347, 1425–1431. 10.1016/s0140-6736(96)91680-3
93
LancasterA. K.Nutter-UphamA.LindquistS.KingO. D. (2014). PLAAC: a Web and Command-Line Application to Identify Proteins with Prion-like Amino Acid Composition. Bioinformatics30, 2501–2502. 10.1093/bioinformatics/btu310
94
Langer-SaferP. R.LevineM.WardD. C. (1982). Immunological Method for Mapping Genes on Drosophila Polytene Chromosomes. Proc. Natl. Acad. Sci.79, 4381–4385. 10.1073/pnas.79.14.4381
95
LeblondC. S.Gan-OrZ.SpiegelmanD.LaurentS. B.SzutoA.HodgkinsonA.et al (2016). Replication Study of MATR3 in Familial and Sporadic Amyotrophic Lateral Sclerosis. Neurobiol. Aging37, 209–e21. 10.1016/j.neurobiolaging.2015.09.013
96
LiJ.OW.LiW.JiangZ.-G.GhanbariH. (2013). Oxidative Stress and Neurodegenerative Disorders. Ijms14, 24438–24475. 10.3390/ijms141224438
97
LimL.WeiY.LuY.SongJ. (2016). ALS-causing Mutations Significantly Perturb the Self-Assembly and Interaction with Nucleic Acid of the Intrinsically Disordered Prion-like Domain of TDP-43. PLOS Biol.14, e1002338–35. 10.1371/journal.pbio.1002338
98
LinK. P.TsaiP. C.LiaoY. C.ChenW. T.TsaiC. P.SoongB. W.et al (2015). Mutational Analysis of MATR3 in Taiwanese Patients with Amyotrophic Lateral Sclerosis. Neurobiol. Aging36, 2005.e4. 10.1016/j.neurobiolaging.2015.02.008
99
LinY.CurrieS. L.RosenM. K. (2017). Intrinsically Disordered Sequences Enable Modulation of Protein Phase Separation through Distributed Tyrosine Motifs. J. Biol. Chem.292, 19110–19120. 10.1074/jbc.M117.800466
100
LinY.ProtterD. S. W.RosenM. K.ParkerR. (2015). Formation and Maturation of Phase-Separated Liquid Droplets by RNA-Binding Proteins. Mol. Cel60, 208–219. 10.1016/j.molcel.2015.08.018
101
MackenzieI. R.RademakersR.NeumannM. (2010). TDP-43 and FUS in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Lancet Neurol.9, 995–1007. 10.1016/s1474-4422(10)70195-2
102
MalikA. M.BarmadaS. J. (2021). Matrin 3 in Neuromuscular Disease: Physiology and Pathophysiology. JCI Insight6, 6. 10.1172/jci.insight.143948
103
MalikA. M.MiguezR. A.LiX.HoY. S.FeldmanE. L.BarmadaS. J. (2018). Matrin 3-dependent Neurotoxicity Is Modified by Nucleic Acid Binding and Nucleocytoplasmic Localization. eLife7, e35977. 10.7554/eLife.35977
104
MalyavanthamK. S.BhattacharyaS.BarbeitosM.MukherjeeL.XuJ.FackelmayerF. O.et al (2008). Identifying Functional Neighborhoods within the Cell Nucleus: Proximity Analysis of Early S-phase Replicating Chromatin Domains to Sites of Transcription, RNA Polymerase II, HP1γ, Matrin 3 and SAF-A. J. Cel. Biochem.105, 391–403. 10.1002/jcb.21834
105
MarangiG.LattanteS.DoronzioP. N.ConteA.TascaG.MonforteM.et al (2017). Matrin 3 Variants Are Frequent in Italian ALS Patients. Neurobiol. Aging49, 218–e7. 10.1016/j.neurobiolaging.2016.09.023
106
Mar´echalA.ZouL. (2013). DNA Damage Sensing by the ATM and ATR Kinases. Cold Spring Harbor Perspect. Biol.5, a012716. 10.1101/cshperspect.a012716
107
MasroriP.Van DammeP. (2020). Amyotrophic Lateral Sclerosis: a Clinical Review. Eur. J. Neurol.27, 1918–1929. 10.1111/ene.14393
108
McAlaryL.ChewY. L.LumJ. S.GeraghtyN. J.YerburyJ. J.CashmanN. R. (2020). Amyotrophic Lateral Sclerosis: Proteins, Proteostasis, Prions, and Promises. Front. Cel. Neurosci.14, 339. 10.3389/fncel.2020.581907
109
McKeeA. C.RobinsonM. E. (2014). Military-related Traumatic Brain Injury and Neurodegeneration. Alzheimers. Dement.10, S242–S253. 10.1016/j.jalz.2014.04.003
110
MejziniR.FlynnL. L.PitoutI. L.FletcherS.WiltonS. D.AkkariP. A. (2019). ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?Front. Neurosci.13, 1310. 10.3389/fnins.2019.01310
111
MesrouzeY.BokhovchukF.IzaacA.MeyerhoferM.ZimmermannC.FontanaP.et al (2018). Adaptation of the Bound Intrinsically Disordered Protein YAP to Mutations at the YAP:TEAD Interface. Protein Sci.27, 1810–1820. 10.1002/pro.3493
112
MészárosB.ErdosG.DosztányiZ. (2018). IUPred2A: Context-dependent Prediction of Protein Disorder as a Function of Redox State and Protein Binding. Nucleic Acids Res.46, W329–W337.
113
MeyerK.KirchnerM.UyarB.ChengJ. Y.RussoG.Hernandez-MirandaL. R.et al (2018). Mutations in Disordered Regions Can Cause Disease by Creating Dileucine Motifs. Cell175, 239–e17. 10.1016/j.cell.2018.08.019
114
MillecampsS.De SeptenvilleA.TeyssouE.DaniauM.CamuzatA.AlbertM.et al (2014). Genetic Analysis of Matrin 3 Gene in French Amyotrophic Lateral Sclerosis Patients and Frontotemporal Lobar Degeneration with Amyotrophic Lateral Sclerosis Patients. Neurobiol. Aging35, 2882–e15. 10.1016/j.neurobiolaging.2014.07.016
115
MiziantyM. J.ZhangT.XueB.ZhouY.DunkerA. K.UverskyV. N.et al (2011). In-silico Prediction of Disorder Content Using Hybrid Sequence Representation. BMC Bioinformatics12, 245. 10.1186/1471-2105-12-245
116
MiziantyM. J.PengZ.KurganL. (2013). MFDp2. Intrinsically Disordered Proteins1, e24428. 10.4161/idp.24428
117
MiziantyM. J.StachW.ChenK.KedarisettiK. D.DisfaniF. M.KurganL. (2010). Improved Sequence-Based Prediction of Disordered Regions with Multilayer Fusion of Multiple Information Sources. Bioinformatics26, i489–i496. 10.1093/bioinformatics/btq373
118
MollicaL.BessaL. M.HanoulleX.JensenM. R.BlackledgeM.SchneiderR. (2016). Binding Mechanisms of Intrinsically Disordered Proteins: Theory, Simulation, and Experiment. Front. Mol. Biosci.3, 52. 10.3389/fmolb.2016.00052
119
MolliexA.TemirovJ.LeeJ.CoughlinM.KanagarajA. P.KimH. J.et al (2015). Phase Separation by Low Complexity Domains Promotes Stress Granule Assembly and Drives Pathological Fibrillization. Cell163, 123–133. 10.1016/j.cell.2015.09.015
120
MonahanZ.RyanV. H.JankeA. M.BurkeK. A.RhoadsS. N.ZerzeG. H.et al (2017). Phosphorylation of the FUS Low‐complexity Domain Disrupts Phase Separation, Aggregation, and Toxicity. EMBO J.36, 2951–2967. 10.15252/embj.201696394
121
MoreiraI. S.MartinsJ. M.RamosR. M.FernandesP. A.RamosM. J. (2013). Understanding the Importance of the Aromatic Amino-Acid Residues as Hot-Spots. Biochim. Biophys. Acta1834, 404–414. 10.1016/j.bbapap.2012.07.005
122
Morriss-AndrewsA.SheaJ.-E. (2015). Computational Studies of Protein Aggregation: Methods and Applications. Annu. Rev. Phys. Chem.66, 643–666. 10.1146/annurev-physchem-040513-103738
123
MoumenA.MastersonP.O'ConnorM. J.JacksonhnRNPS. P. K. (2005). hnRNP K: An HDM2 Target and Transcriptional Coactivator of P53 in Response to DNA Damage. Cell123, 1065–1078. 10.1016/j.cell.2005.09.032
124
NakayasuH.BerezneyR. (1991). Nuclear Matrins: Identification of the Major Nuclear Matrix Proteins. Proc. Natl. Acad. Sci.88, 10312–10316. 10.1073/pnas.88.22.10312
125
NeumannM.KwongL. K.TruaxA. C.VanmassenhoveB.KretzschmarH. A.Van DeerlinV. M.et al (2007). TDP-43-Positive White Matter Pathology in Frontotemporal Lobar Degeneration with Ubiquitin-Positive Inclusions. J. Neuropathol. Exp. Neurol.66, 177–183. 10.1097/01.jnen.0000248554.45456.58
126
NeumannM.SampathuD. M.KwongL. K.TruaxA. C.MicsenyiM. C.ChouT. T.et al (2006). Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Science314, 130–133. 10.1126/science.1134108
127
NevoneA.MerliniG.NuvoloneM. (2020). Treating Protein Misfolding Diseases: Therapeutic Successes against Systemic Amyloidoses. Front. Pharmacol.11, 1024. 10.3389/fphar.2020.01024
128
NguyenC. D.MansfieldR. E.LeungW.VazP. M.LoughlinF. E.GrantR. P.et al (2011). Characterization of a Family of RanBP2-type Zinc Fingers that Can Recognize Single-Stranded RNA. J. Mol. Biol.407, 273–283. 10.1016/j.jmb.2010.12.041
129
NielsenJ. T.MulderF. A. A. (2019). Quality and Bias of Protein Disorder Predictors. Sci. Rep.9, 5137. 10.1038/s41598-019-41644-w
130
Niimori-KitaK.TamamakiN.KoizumiD.NiimoriD. (2018). Matrin-3 Is Essential for Fibroblast Growth Factor 2-dependent Maintenance of Neural Stem Cells. Sci. Rep.8, 13412. 10.1038/s41598-018-31597-x
131
NottT. J.PetsalakiE.FarberP.JervisD.FussnerE.PlochowietzA.et al (2015). Phase Transition of a Disordered Nuage Protein Generates Environmentally Responsive Membraneless Organelles. Mol. Cel57, 936–947. 10.1016/j.molcel.2015.01.013
132
OldfieldC. J.DunkerA. K. (2014). Intrinsically Disordered Proteins and Intrinsically Disordered Protein Regions. Annu. Rev. Biochem.83, 553–584. 10.1146/annurev-biochem-072711-164947
133
OrigoneP.VerdianiS.Bandettini Di PoggioM.ZuccarinoR.VignoloM.CaponnettoC.et al (2015). A Novel Arg147Trp MATR3 Missense Mutation in a Slowly Progressive ALS Italian Patient. Amyotroph. Lateral Scler. Frontotemporal Degeneration16, 530–531. 10.3109/21678421.2015.1058397
134
OwenI.ShewmakerF. (2019). The Role of Post-Translational Modifications in the Phase Transitions of Intrinsically Disordered Proteins. Int. J. Mol. Sci.20, 5501. 10.3390/ijms20215501
135
PakravanD.OrlandoG.BercierV.Van Den BoschL. (2020). Role and Therapeutic Potential of Liquid-Liquid Phase Separation in Amyotrophic Lateral Sclerosis. J. Mol. Cel Biol.13, 15–28. 10.1093/jmcb/mjaa049
136
PaloniM.BaillyR.CiandriniL.BarducciA. (2020). Unraveling Molecular Interactions in Liquid-Liquid Phase Separation of Disordered Proteins by Atomistic Simulations. J. Phys. Chem. B124, 9009–9016. 10.1021/acs.jpcb.0c06288
137
ParakhS.AtkinJ. D. (2016). Protein Folding Alterations in Amyotrophic Lateral Sclerosis. Brain Res.1648, 633–649. 10.1016/j.brainres.2016.04.010
138
PatelA.LeeH. O.JawerthL.MaharanaS.JahnelM.HeinM. Y.et al (2015). A Liquid-To-Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation. Cell162, 1066–1077. 10.1016/j.cell.2015.07.047
139
Pérez-GonzálezA.GalanoA. (2011). OH Radical Scavenging Activity of Edaravone: Mechanism and Kinetics. J. Phys. Chem. B115, 1306–1314. 10.1021/jp110400t
140
PetrovD.MansfieldC.MoussyA.HermineO. (2017). ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?Front. Aging Neurosci.9, 68. 10.3389/fnagi.2017.00068
141
PickartC. M. (2001). Mechanisms Underlying Ubiquitination. Annu. Rev. Biochem.70, 503–533. 10.1146/annurev.biochem.70.1.503
142
PietrekL. M.StelzlL. S.HummerG. (2020). Hierarchical Ensembles of Intrinsically Disordered Proteins at Atomic Resolution in Molecular Dynamics Simulations. J. Chem. Theor. Comput.16, 725–737. 10.1021/acs.jctc.9b00809
143
PiovesanD.TabaroF.Miˇceti´cI.NecciM.QuagliaF.OldfieldC. J.et al (2016). DisProt 7.0: a Major Update of the Database of Disordered Proteins. Nucleic Acids Res.45, D1123–D1124. 10.1093/nar/gkw1056
144
PollariE.GoldsteinsG.BartG. v.KoistinahoJ.GiniatullinR. (2014). The Role of Oxidative Stress in Degeneration of the Neuromuscular junction in Amyotrophic Lateral Sclerosis. Front. Cel. Neurosci.8, 131. 10.3389/fncel.2014.00131
145
PrasadA.BharathiV.SivalingamV.GirdharA.PatelB. K. (2019). Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis. Front. Mol. Neurosci.12, 25. 10.3389/fnmol.2019.00025
146
Project MinE Als Sequencing Consortium (2018). Project MinE: Study Design and Pilot Analyses of a Large-Scale Whole-Genome Sequencing Study in Amyotrophic Lateral Sclerosis. Eur. J. Hum. Genet.26, 1537–1546. 10.1038/s41431-018-0177-4
147
RadivojacP.IakouchevaL. M.OldfieldC. J.ObradovicZ.UverskyV. N.DunkerA. K. (2007). Intrinsic Disorder and Functional Proteomics. Biophysical J.92, 1439–1456. 10.1529/biophysj.106.094045
148
RajeshC.GruverA. M.BasrurV.PittmanD. L. (2009). The Interaction Profile of Homologous Recombination Repair Proteins RAD51C, RAD51D and XRCC2 as Determined by Proteomic Analysis. Proteomics9, 4071–4086. 10.1002/pmic.200800977
149
RameshN.KourS.AndersonE. N.RajasundaramD.PandeyU. B. (2020). RNA-recognition Motif in Matrin-3 Mediates Neurodegeneration through Interaction with hnRNPM. Acta Neuropathol. Commun.8, 138. 10.1186/s40478-020-01021-5
150
RamisR.Ortega-CastroJ.CasasnovasR.MariñoL.VilanovaB.AdroverM.et al (2019). A Coarse-Grained Molecular Dynamics Approach to the Study of the Intrinsically Disordered Protein α-Synuclein. J. Chem. Inf. Model.59, 1458–1471. 10.1021/acs.jcim.8b00921
151
RhoadsS. N.MonahanZ. T.YeeD. S.ShewmakerF. P. (2018). The Role of Post-Translational Modifications on Prion-like Aggregation and Liquid-phase Separation of FUS. Int. J. Mol. Sci.19, 886. 10.3390/ijms19030886
152
RomeroP.ObradovicZ.LiX.GarnerE. C.BrownC. J.DunkerA. K. (2001). Sequence Complexity of Disordered Protein. Proteins42, 38–48. 10.1002/1097-0134(20010101)42:1<38:aid-prot50>3.0.co;2-3
153
SaarK. L.MorgunovA. S.QiR.ArterW. E.KrainerG.LeeA. A.et al (2021). Learning the Molecular Grammar of Protein Condensates from Sequence Determinants and Embeddings. Proc. Natl. Acad. Sci. USA118, e2019053118. 10.1073/pnas.2019053118
154
Saez-AtienzarS.DalgardC. L.DingJ.ChiòA.AlbaC.HupaloD. N.et al (2020). Identification of a Pathogenic Intronic KIF5A Mutation in an ALS-FTD kindred. Neurology95, 1015–1018. 10.1212/wnl.0000000000011064
155
SaltonM.ElkonR.BorodinaT.DavydovA.YaspoM. L.HalperinE.et al (2011). Matrin 3 Binds and Stabilizes mRNA. PLOS ONE6, e23882–7. 10.1371/journal.pone.0023882
156
SaltonM.LerenthalY.WangS.-Y.ChenD. J.ShilohY. (2010). Involvement of Matrin 3 and SFPQ/NONO in the DNA Damage Response. Cell Cycle9, 1568–1576. 10.4161/cc.9.8.11298
157
SantamariaN.AlhothaliM.AlfonsoM. H.BreydoL.UverskyV. N. (2017). Intrinsic Disorder in Proteins Involved in Amyotrophic Lateral Sclerosis. Cell. Mol. Life Sci.74, 1297–1318. 10.1007/s00018-016-2416-6
158
SchaffertL. N.CarterW. G. (2020). Do Post-Translational Modifications Influence Protein Aggregation in Neurodegenerative Diseases: A Systematic Review. Brain Sci.10, 232. 10.3390/brainsci10040232
159
SchmidtH. B.GörlichD. (2016). Transport Selectivity of Nuclear Pores, Phase Separation, and Membraneless Organelles. Trends Biochem. Sci.41, 46–61. 10.1016/j.tibs.2015.11.001
160
SchragL. G.LiuX.ThevarajanI.PrakashO.ZolkiewskiM.ChenJ. (2021). Cancer-Associated Mutations Perturb the Disordered Ensemble and Interactions of the Intrinsically Disordered P53 Transactivation Domain. J. Mol. Biol.433, 167048. 10.1016/j.jmb.2021.167048
161
SenderekJ.GarveyS. M.KriegerM.GuergueltchevaV.UrtizbereaA.RoosA.et al (2009). Autosomal-Dominant Distal Myopathy Associated with a Recurrent Missense Mutation in the Gene Encoding the Nuclear Matrix Protein, Matrin 3. Am. J. Hum. Genet.84, 511–518. 10.1016/j.ajhg.2009.03.006
162
SharmaR.RadulyZ.MiskeiM.FuxreiterM. (2015). Fuzzy Complexes: Specific Binding without Complete Folding. FEBS Lett.589, 2533–2542. 10.1016/j.febslet.2015.07.022
163
SieradzanA. K.KorneevA.BegunA.KachlishviliK.ScheragaH. A.MolochkovA.et al (2021). Investigation of Phosphorylation-Induced Folding of an Intrinsically Disordered Protein by Coarse-Grained Molecular Dynamics. J. Chem. Theor. Comput.17, 3203–3220. 10.1021/acs.jctc.1c00155
164
SongJ.NgS. C.TompaP.LeeK. A.ChanH. S. (2013). Polycation-π Interactions Are a Driving Force for Molecular Recognition by an Intrinsically Disordered Oncoprotein Family. PLOS Comput. Biol.9, e1003239–12. 10.1371/journal.pcbi.1003239
165
SotoC. (2003). Unfolding the Role of Protein Misfolding in Neurodegenerative Diseases. Nat. Rev. Neurosci.4, 49–60. 10.1038/nrn1007
166
SteinackerP.BarschkeP.OttoM. (2019). Biomarkers for Diseases with TDP-43 Pathology. Mol. Cell Neurosci.97, 43–59. 10.1016/j.mcn.2018.10.003
167
StrandeN. T.RiggsE. R.BuchananA. H.Ceyhan-BirsoyO.DiStefanoM.DwightS. S.et al (2017). Evaluating the Clinical Validity of Gene-Disease Associations: An Evidence-Based Framework Developed by the Clinical Genome Resource. Am. J. Hum. Genet.100, 895–906. 10.1016/j.ajhg.2017.04.015
168
SuX.DitlevJ. A.HuiE.XingW.BanjadeS.OkrutJ.et al (2016). Phase Separation of Signaling Molecules Promotes T Cell Receptor Signal Transduction. Science352, 595–599. 10.1126/science.aad9964
169
SukT. R.RousseauxM. W. C. (2020). The Role of TDP-43 Mislocalization in Amyotrophic Lateral Sclerosis. Mol. Neurodegener.15, 45. 10.1186/s13024-020-00397-1
170
SzklarczykD.GableA. L.LyonD.JungeA.WyderS.Huerta-CepasJ.et al (2018). STRING V11: Protein-Protein Association Networks with Increased Coverage, Supporting Functional Discovery in Genome-wide Experimental Datasets. Nucleic Acids Res.47, D607–D613. 10.1093/nar/gky1131
171
TadaM.DoiH.KoyanoS.KubotaS.FukaiR.HashiguchiS.et al (2018). Matrin 3 Is a Component of Neuronal Cytoplasmic Inclusions of Motor Neurons in Sporadic Amyotrophic Lateral Sclerosis. Am. J. Pathol.188, 507–514. 10.1016/j.ajpath.2017.10.007
172
TangH.GaiettaG. M.FischerW. H.EllismanM. H.Wong-StaalF. (1997). A Cellular Cofactor for the Constitutive Transport Element of Type D Retrovirus. Science276, 1412–1415. 10.1126/science.276.5317.1412
173
The UniProt Consortium (2018). UniProt: a Worldwide Hub of Protein Knowledge. Nucleic Acids Res.47, D506–D515. 10.1093/nar/gky1049
174
TheilletF.-X.KalmarL.TompaP.HanK.-H.SelenkoP.DunkerA. K.et al (2013). The Alphabet of Intrinsic Disorder. Intrinsically Disordered Proteins1, e24360. 10.4161/idp.24360
175
TompaP.FuxreiterM. (2008). Fuzzy Complexes: Polymorphism and Structural Disorder in Protein-Protein Interactions. Trends Biochem. Sci.33, 2–8. 10.1016/j.tibs.2007.10.003
176
TompaP.SchadE.TantosA.KalmarL. (2015). Intrinsically Disordered Proteins: Emerging Interaction Specialists. Curr. Opin. Struct. Biol.35, 49–59. 10.1016/j.sbi.2015.08.009
177
TompaP.SzászC.BudayL. (2005). Structural Disorder Throws New Light on Moonlighting. Trends Biochem. Sci.30, 484–489. 10.1016/j.tibs.2005.07.008
178
TuroverovK. K.KuznetsovaI. M.UverskyV. N. (2010). The Protein Kingdom Extended: Ordered and Intrinsically Disordered Proteins, Their Folding, Supramolecular Complex Formation, and Aggregation. Prog. Biophys. Mol. Biol.102, 73–84. 10.1016/j.pbiomolbio.2010.01.003
179
TyzackG. E.LuisierR.TahaD. M.NeevesJ.ModicM.MitchellJ. S.et al (2019). Widespread FUS Mislocalization Is a Molecular Hallmark of Amyotrophic Lateral Sclerosis. Brain142, 2572–2580. 10.1093/brain/awz217
180
UemuraY.OshimaT.YamamotoM.ReyesC. J.Costa CruzP. H.ShibuyaT.et al (2017). Matrin3 Binds Directly to Intronic Pyrimidine-Rich Sequences and Controls Alternative Splicing. Genes Cells22, 785–798. 10.1111/gtc.12512
181
UverskyV. N.GillespieJ. R.FinkA. L. (2000). Why Are ?natively Unfolded? Proteins Unstructured under Physiologic Conditions?Proteins41, 415–427. 10.1002/1097-0134(20001115)41:3<415:aid-prot130>3.0.co;2-7
182
UverskyV. N. (2019). Intrinsically Disordered Proteins and Their “Mysterious” (Meta)Physics. Front. Phys.7, 10. 10.3389/fphy.2019.00010
183
UverskyV. N. (2011). Multitude of Binding Modes Attainable by Intrinsically Disordered Proteins: a Portrait Gallery of Disorder-Based Complexes. Chem. Soc. Rev.40, 1623–1634. 10.1039/c0cs00057d
184
UverskyV. N. (2017). Paradoxes and Wonders of Intrinsic Disorder: Stability of Instability. Intrinsically Disordered Proteins5, e1327757. 10.1080/21690707.2017.1327757
185
UverskyV. N. (2013). The Alphabet of Intrinsic Disorder. Intrinsically Disordered Proteins1, e24684. 10.4161/idp.24684
186
UverskyV. N. (2013). Unusual Biophysics of Intrinsically Disordered Proteins. Biochim. Biophys. Acta1834, 932–951. 10.1016/j.bbapap.2012.12.008
187
VacicV.MarkwickP. R.OldfieldC. J.ZhaoX.HaynesC.UverskyV. N.et al (2012). Disease-Associated Mutations Disrupt Functionally Important Regions of Intrinsic Protein Disorder. PLOS Comput. Biol.8, e1002709–14. 10.1371/journal.pcbi.1002709
188
van der LeeR.BuljanM.LangB.WeatherittR. J.DaughdrillG. W.DunkerA. K.et al (2014). Classification of Intrinsically Disordered Regions and Proteins. Chem. Rev.114, 6589–6631. 10.1021/cr400525m
189
van EsM. A.HardimanO.ChioA.Al-ChalabiA.PasterkampR. J.VeldinkJ. H.et al (2017). Amyotrophic Lateral Sclerosis. The Lancet390, 2084–2098. 10.1016/s0140-6736(17)31287-4
190
WatanabeS.InamiH.OiwaK.MurataY.SakaiS.KomineO.et al (2020). Aggresome Formation and Liquid-Liquid Phase Separation Independently Induce Cytoplasmic Aggregation of TAR DNA-Binding Protein 43. Cell Death Dis11, 909. 10.1038/s41419-020-03116-2
191
WegmannS.EftekharzadehB.TepperK.ZoltowskaK. M.BennettR. E.DujardinS.et al (2018). Tau Protein Liquid-Liquid Phase Separation Can Initiate Tau Aggregation. EMBO J.37, e98049. 10.15252/embj.201798049
192
WilsonC. J.ChangM.KarttunenM.ChoyW.-Y. (2021). KEAP1 Cancer Mutants: A Large-Scale Molecular Dynamics Study of Protein Stability. Int. J. Mol. Sci.22, 5408. 10.3390/ijms22105408
193
WilsonC. J.ChoyW.-Y.KarttunenM. (2021). AlphaFold2: A Role for Disordered Protein Prediction?bioRxiv. 10.1101/2021.09.27.461910
194
WongE. T. C.SoV.GuronM.KuechlerE. R.MalhisN.BuiJ. M.et al (2020). Protein-Protein Interactions Mediated by Intrinsically Disordered Protein Regions Are Enriched in Missense Mutations. Biomolecules10. 10.3390/biom10081097
195
WrightP. E.DysonH. J. (2015). Intrinsically Disordered Proteins in Cellular Signalling and Regulation. Nat. Rev. Mol. Cel Biol.16, 18–29. 10.1038/nrm3920
196
XuL.LiJ.TangL.ZhangN.FanD. (2016). MATR3 Mutation Analysis in a Chinese Cohort with Sporadic Amyotrophic Lateral Sclerosis. Neurobiol. Aging38, 218–e4. 10.1016/j.neurobiolaging.2015.11.023
197
XueB.DunbrackR. L.WilliamsR. W.DunkerA. K.UverskyV. N. (2010). PONDR-FIT: A Meta-Predictor of Intrinsically Disordered Amino Acids. Biochim. Biophys. Acta (Bba) - Proteins Proteomics1804, 996–1010. 10.1016/j.bbapap.2010.01.011
198
YamaguchiA.TakanashiK. (2016). FUS Interacts with Nuclear Matrix-Associated Protein SAFB1 as Well as Matrin3 to Regulate Splicing and Ligand-Mediated Transcription. Sci. Rep.6, 35195. 10.1038/srep35195
199
YamamotoY.KuwaharaT.WatanabeK.WatanabeK. (1996). Antioxidant Activity of 3-Methyl-1-Phenyl-2-Pyrazolin-5-One. Redox Rep.2, 333–338. 10.1080/13510002.1996.11747069
200
ZareiS.CarrK.ReileyL.DiazK.GuerraO.AltamiranoP. F.et al (2015). A Comprehensive Review of Amyotrophic Lateral Sclerosis. Surg. Neurol. Int.6, 171. 10.4103/2152-7806.169561
201
ZbindenA.Pérez-BerlangaM.De RossiP.PolymenidouM. (2020). Phase Separation and Neurodegenerative Diseases: A Disturbance in the Force. Develop. Cel55, 45–68. 10.1016/j.devcel.2020.09.014
202
ZeitzM. J.MalyavanthamK. S.SeifertB.BerezneyR. (2009). Matrin 3: Chromosomal Distribution and Protein Interactions. J. Cel. Biochem.108, 125–133. 10.1002/jcb.22234
Summary
Keywords
Matrin3, ALS, proteinopathy, intrinsically disordered domains, protein misfolding
Citation
Salem A, Wilson CJ, Rutledge BS, Dilliott A, Farhan S, Choy W-Y and Duennwald ML (2022) Matrin3: Disorder and ALS Pathogenesis. Front. Mol. Biosci. 8:794646. doi: 10.3389/fmolb.2021.794646
Received
13 October 2021
Accepted
30 November 2021
Published
10 January 2022
Volume
8 - 2021
Edited by
Pietro Sormanni, University of Cambridge, United Kingdom
Reviewed by
Carlo Camilloni, University of Milan, Italy
Leonid Breydo, West Pharmaceutical Services, United States
Updates
Copyright
© 2022 Salem, Wilson, Rutledge, Dilliott, Farhan, Choy and Duennwald.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Martin L. Duennwald, martin.duennwald@schulich.uwo.ca
† These authors have contributed equally to this work
This article was submitted to Protein Folding, Misfolding and Degradation, a section of the journal Frontiers in Molecular Biosciences
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.